Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors

Science. 2004 Oct 15;306(5695):384-5. doi: 10.1126/science.306.5695.384.
No abstract available

Publication types

  • News

MeSH terms

  • Blood Pressure / drug effects
  • Clinical Trials as Topic
  • Colonic Polyps / prevention & control
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / pharmacokinetics
  • Cyclooxygenase Inhibitors / pharmacology
  • Cyclooxygenase Inhibitors / therapeutic use
  • Drug Industry*
  • Drug and Narcotic Control
  • Humans
  • Lactones / adverse effects*
  • Lactones / pharmacokinetics
  • Lactones / pharmacology
  • Lactones / therapeutic use
  • Myocardial Infarction / chemically induced
  • Product Surveillance, Postmarketing
  • Stroke / chemically induced
  • Sulfones
  • Thrombosis / chemically induced

Substances

  • Cyclooxygenase Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib